. Here we show that human KL cells and tumours share metabolomic signatures of perturbed nitrogen handling. KL cells express the urea cycle enzyme carbamoyl phosphate synthetase-1 (CPS1), which produces carbamoyl phosphate in the mitochondria from ammonia and bicarbonate, initiating nitrogen disposal. Transcription of CPS1 is suppressed by LKB1 through AMPK, and CPS1 expression correlates inversely with LKB1 in human NSCLC. Silencing CPS1 in KL cells induces cell death and reduces tumour growth. Notably, cell death results from pyrimidine depletion rather than ammonia toxicity, as CPS1 enables an unconventional pathway of nitrogen flow from ammonia into pyrimidines. CPS1 loss reduces the pyrimidine to purine ratio, compromises S-phase progression and induces DNA-polymerase stalling and DNA damage. Exogenous pyrimidines reverse DNA damage and rescue growth. The data indicate that the KL oncological genotype imposes a metabolic vulnerability related to a dependence on a cross-compartmental pathway of pyrimidine metabolism in an aggressive subset of NSCLC.
LETTER RESEARCH
In the urea cycle, mitochondrial carbamoyl phosphate condenses with ornithine to produce citrulline, which is exported to the cytosol and converted into arginine (Fig. 1b) . Although the cytosolic enzymes are broadly expressed, the mitochondrial enzymes, including CPS1, are largely confined to hepatocytes, restricting robust urea production from ammonia to the liver 5 . Somatic ASS1 and ASL loss in some tumour cells promotes proliferation by increasing aspartate availability for other pathways 6 . To assess the cytosolic segment, we deprived cells of arginine and measured growth in the presence and absence of exogenous citrulline. Arginine depletion suppressed growth of all lines, but KL cells were protected by the addition of citrulline, indicating that these cells are able to generate arginine from citrulline (Fig. 1d) . Neither ornithine nor nitric oxide was protective, indicating that a complete cycle in KL cells is lacking and nitric oxide is not an essential by-product of this pathway in KL cells (Fig. 1d) . KL cells were also not selectively sensitive to silencing of ornithine decarboxylase, which initiates conversion of ornithine to polyamines (Extended Data Fig. 4d ).
We used orthogonal data from 94 lung cancer cell lines including 14 K, 16 L (loss of LKB1) and 9 KL lines (Supplementary Table 7 ) to examine the relationship between CPS1 and LKB1. Reversed-phase proteomics identified LKB1 as the most negatively correlated to CPS1 mRNA among 176 proteins and phosphoproteins (Extended Data Fig. 4e and Supplementary Table 8 ). Transcriptome analysis covering 19,579 genes ranked CPS1 as the second most inversely correlated mRNA with LKB1 protein (Fig. 2a and Supplementary Table 9) . A human lung tumour tissue microarray detected CPS1 protein in 18% of samples, and tumours with intense or moderate CPS1 staining expressed little to no LKB1 protein ( Fig. 2b and Extended Data Fig. 4f, g ). In human lung adenocarcinoma, tumours with abundant CPS1 mRNA were highly enriched for LKB1 loss (Fig. 2c) . CPS1 was also expressed in patient-derived NSCLC xeno grafts, but only in LKB1-deficient tumours (Extended Data  Fig. 4h ). Abundant CPS1 mRNA correlates with poor prognosis in NSCLC (Extended Data Fig. 4i ).
To test whether LKB1 regulates CPS1 expression, we engineered KL cells to express wild-type or kinase-dead LKB1 (LKB1-WT or LKB1-KD). Expression of LKB1-WT but not LKB1-KD reduced CPS1 expression (Fig. 2d , e and Extended Data Fig. 5a -c), although as recently reported 7 , neither silencing LKB1 nor activating AMPK in K cells altered CPS1 (Extended Data Fig. 5d ). LKB1 induces metabolic effects through the fuel sensor AMPK 8, 9 . In KL cells, pharmacological activation of AMPK or expression of constitutively active AMPK reduced CPS1 mRNA and protein, and silencing AMPK increased CPS1 expression even in the presence of LKB1 (Fig. 2f and Extended Data Fig. 5e-h ). Although AMPK inhibits mTOR, neither inhibition nor activation of mTOR affected CPS1 expression (Extended Data Fig. 5i, j) .
Chromatin immunoprecipitation (ChIP) followed by sequencing (ChIP-seq) data of the CPS1 locus in A549 (KL) cells contained chromatin features consistent with an enhancer element in intron 1 (Extended Data Fig. 6a ). ChIP-qPCR revealed markedly increased histone H3K27 acetylation, H3K4 trimethylation and RNA polymerase-II binding at this enhancer in KL compared to K cells, with AMPK activation reducing these signals (Extended Data Fig. 6b, c) . FOXA1, CREB1 and TEAD4, three transcription factors repressed by AMPK [10] [11] [12] , also displayed enhanced binding in KL cells, with binding inhibited upon AMPK activation (Extended Data Fig. 6b, c) . Silencing of FOXA1 reduced CPS1 mRNA and protein (Extended Data Fig. 6d, e) .
Next, NSCLC cell lines were transfected with CPS1-targeting or control short interfering RNAs (siRNAs). CPS1 silencing reduced viability in KL lines, but other cell lines, including L cells expressing CPS1, tolerated CPS1 silencing (Fig. 3a, b and Extended Data Fig. 7a, b) . Among five KL cell lines, only A549 tolerated CPS1 silencing, although even these cells trended towards reduced viability (Extended Data Fig. 7c ). Deleting CPS1 using CRISPR-Cas9 reduced KL cell viability (Extended Data Fig. 7d , e) and LKB1-WT protected KL cells against CPS1 silencing or knockout ( Fig. 3c and Extended Data Fig. 7f ). To control the timing of CPS1 silencing, we generated KL cells with doxycycline (Dox)-inducible expression of CPS1 short hairpin RNA (shRNA; shCPS1-1 and shCPS1-2) or Renilla luciferase shRNA as a control (shREN) (Extended Data Fig. 7g ). In H460 (KL) cells, CPS1 depletion increased the doubling time, Right, LKB1 expression in each CPS1 expression group (total n = 180). c, CPS1 mRNA abundance in human lung adenocarcinoma (n = 483). LKB1 mutants (mut) are shown in red. RPKM, reads per kilobase per million reads; WT, wild type. d, Urea cycle-related enzyme expression in control H460 cells (EV, empty vector, n = 3) and cells expressing wild-type (n = 3) or kinase-dead (KD; K78I mutant, n = 3) LKB1. e, CPS1, LKB1 and phosphorylated acetyl-CoA carboxylase (pACC, S79) abundance upon LKB1 re-expression. f, CPS1, total and pACC abundance in A549, H2122 and H460 cells treated with the AMPK activator A769662. Statistical significance was assessed using a two-tailed Student's t-test (c) or one-way ANOVA followed by Tukey's multiple comparisons test (d). * * P < 0.01. TMA was performed once and all other experiments were repeated three times or more.
induced cell death and suppressed colony formation in soft agar ( Fig. 3d-f ). An shRNA-resistant mouse Cps1 cDNA protected viability (Extended Data Fig. 7h ). Nude mice were injected subcutaneously with H460 cells expressing shREN, shCPS1-1 or shCPS1-2 and treated with or without Dox. Dox induction of shCPS1 reduced tumour growth and enhanced cell death ( Fig. 3g and Extended Data Figs 7i, 8a). CPS1 silencing also suppressed growth of H2122 (KL) tumours (Extended Data Fig. 8b, c) .
A potential explanation for the reliance of KL cells on CPS1 is a heightened requirement to detoxify ammonia. However, silencing CPS1 only marginally increased ammonia secretion (Extended Data Fig. 9a, b) . Carbamoyl phosphate is also the initiating metabolite in pyrimidine synthesis. This pool of carbamoyl phosphate arises in the cytosol from CPS2, part of the trifunctional CAD enzyme (carbamoyl-phosphate synthetase 2, aspartate transcarbamoylase, and dihydroorotase) catalysing the first three steps of pyrimidine synthesis 13, 14 . The enzymatic activity of CAD is distinct from CPS1, as it uses glutamine rather than ammonia as the nitrogen source. CAD abundance and activation as reported by S1859 phosphorylation 15 were unchanged between K and KL cells, and neither CPS1 siRNAs nor CRISPR-Cas9 had off-target effects on CAD (Extended Data Fig. 9c, d) . Analysis of the CAD genomic locus revealed no consistent differences in epigenetic features or FOXA1, CREB1 and TEAD4 binding between K and KL cells, and silencing these transcription factors did not alter CAD expression (Extended Data Fig. 10a-d) . These findings indicate that CPS1 and CAD transcription are regulated through distinct mechanisms.
Although mitochondrial and cytosolic carbamoyl phosphate generally function as distinct pools, germline deficiency of ornithine carbamoyltransferase (OTC) results in systemic pyrimidine accumulation, indicating that mitochondrial carbamoyl phosphate feeds pyrimidine synthesis under some circumstances 16 . CPS1 silencing in H460 cells resulted in pyrimidine depletion, purine accumulation and a decreased pyrimidine to purine ratio ( Fig. 4a and Extended Data Fig. 9e ). Furthermore, incubating cells with 15 NH 4 + revealed CPS1-dependent transfer of this nitrogen into thymidine, a pyrimidine nucleoside (Fig. 4b) . Thus, KL cells use CPS1 to maintain pyrimidine pools.
Because disruption of the pyrimidine/purine balance impairs DNA replication 17, 18 , we examined cell cycle distribution during CPS1 silencing. 5-Bromodeoxyuridine (BrdU) incorporation and DNA content analysis revealed cellular accumulation in an ineffective S phase (less BrdU incorporation) (Extended Data Fig. 9f, g ). G2/M accumulation also occurred in p53-competent H460 cells but not p53-mutant H2122 cells (Extended Data Fig. 9g ). Prolonged inhibition of DNA replication induces double-stranded DNA breaks and cell death 19, 20 , suggesting a mechanism for CPS1 addiction. Indeed, CPS1-silenced cells and xenografts, but not shREN controls demonstrated increased histone H2AX phosphorylation (γ H2AX S319) ( Fig. 4c and Extended Data Fig. 9h, i) , indicating that CPS1 is required to prevent double-stranded DNA breaks. Double-stranded DNA breaks associated with altered pyrimidine to purine ratios can result from replication-fork stalling 21 , so we performed DNA fibre assays to monitor progression of individual DNA replication forks in the presence and absence of CPS1. Control cells incorporated 5-iodo-2′ -deoxyuridine (IdU) and 5-chloro-2′ -deoxyuridine (CldU) into long DNA tracks, but CPS1-silenced cells exhibited short tracks, indicating impairment of replication progression (Extended Data Fig. 9j ). Supplementing CPS1-silenced cells with pyrimidine nucleosides but not purine nucleosides prevented γ H2AX phosphorylation and rescued replication-fork stalling (Fig. 4d , e and Extended Data Fig. 10e ). Pyrimidines but not purines also norma- In c-f, statistical significance was assessed using a one-way ANOVA followed by Tukey's multiple comparisons test. In g, to calculate significance on repeated measurements over time, a two-way ANOVA was used. The mouse xenograft experiment was performed twice for shCPS1-1 (n = 5 mice per experiment, total n = 10) and once for shCPS1-2 and shREN (n = 10). All other experiments were repeated three times or more. * * P < 0.01; * * * P < 0.001; * * * * P < 0.0001. NS, not significant. lized proliferation and colony formation in CPS1-silenced cells ( Fig. 4f and Extended Data Fig. 10e-i) . Finally, cisplatin, a DNA-damaging agent and first-line therapeutic in NSCLC, was combined with CPS1 silencing to reduce growth of KL tumours ( Fig. 4g and Extended Data Fig. 10j, k) .
Cancer cells reprogram metabolism to support survival and proliferation, and particular oncogenic genotypes impose specific vulnerabilities 22 . Because both KRAS and LKB1 regulate metabolism, co-mutation of the two genes might specify metabolic phenotypes not observed with either mutation alone, perhaps contributing to the aggressive oncological behaviour of co-mutant tumours. In mice, co-mutation of KRAS and LKB1 in lung tumours imposes a state of dependence on enzymes involved in conventional pyrimidine biosynthesis 3 . The surprising requirement of CPS1, a urea cycle enzyme, to maintain the purine/pyrimidine balance in human KL cells implies that this enzyme provides an alternative pool of carbamoyl phosphate to maintain pyrimidine availability. Disrupting this balance by reducing the contribution of CPS1 to pyrimidine metabolism severely altered DNA-polymerase processivity, resulting in DNA damage and cell death. The fact that L cells with wild-type KRAS express, but do not require, CPS1 suggests that the metabolic effects of oncogenic KRAS are essential for CPS1 addiction. It is interesting that oncogenic KRAS stimulates glutamine catabolism in the mitochondria 23 , perhaps creating a local supply of ammonia for CPS1 while reducing glutamine availability for CAD-mediated pyrimidine biosynthesis in the cytosol (Extended Data Fig. 1a) . Our findings suggest the use of CPS1 or related pathway components as therapeutic targets in KL mutant lung adenocarcinomas, providing both enrollment biomarkers (KL oncogenic genotype plus CPS1 expression) and a new mechanism of oncogene addiction.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. For experiments in cell lines, data are mean ± s.d. of three independent cultures. Significance was assessed using a two-tailed Student's t-test (a), one-way ANOVA with Tukey's multiple comparisons test (b, e, f) or two-way ANOVA with Tukey's multiple comparisons test (g). In e, * P < 0.05 compared to shREN; #P < 0.05 compared to shCPS1; †P < 0.05 compared to shCPS1 and uridine and thymidine (UT). In f, * P < 0.05 compared to no treatment; #P < 0.05 compared to + Dox with no nucleoside supplementation, †P < 0.05 compared to Dox and uridine and thymidine (UT). In g, * P < 0.05 compared to − Dox and − Cis; #P < 0.05 compared to − Dox and + Cis; †P < 0.05 compared to + Dox and − Cis. In all other panels: * * P < 0.01; * * * P < 0.001. Nucleotide measurements and DNA fibre assays were performed twice. All other experiments were repeated three times or more. 
Supplementary Information is available in the online version of the paper.

METHODS
Cell lines, culture and reagents. All NSCLC cell lines (A549, H1355, H157, H2122,  Hcc515, H460, H1395, H1437, H1755, H1993, H2023, H2073, H1373, H2347,  H358 , H441, Calu-1 and Calu-6) used in this study were obtained from the Hamon Cancer Center Collection (University of Texas-Southwestern Medical Center). Cells were maintained in RPMI-1640 supplemented with penicillin-streptomycin, and 5% fetal bovine serum (FBS) at 37 °C in a humidified atmosphere containing 5% CO 2 and 95% air. All cell lines have been DNA fingerprinted for provenance using the PowerPlex 1.2 kit (Promega) and were mycoplasma-free using the e-Myco kit (Boca Scientific). H460-EV, H460-LKB1-WT and H460-LKB1-KD were gene rated by infecting H460 cells with pBABE retroviral vectors expressing no cDNA or cDNAs encoding wild-type or kinase-dead (K78I mutant) LKB1, respectively. pBABE-FLAG-LKB1-WT and -KD were from L. Cantley (Addgene plasmid 8592 and 8593, respectively) and pAMPK alpha2 delta312X (constitutively active AMPK) was from M. Birnbaum (Addgene plasmid 60127). For mouse CPS1 (mCPS1) cloning, mCPS1 cDNA was purchased from GE healthcare (cloneID 40098767), and subcloned into pWPXL lentiviral plasmid (Addgene, plasmid 12257). Stable integrants were sorted by flow cytometry (FACS Aria II SORP) for further analyses. To generate H460-shREN and -shCPS1 cells, parental H460 cells were infected by TRMPVIR retroviral vectors expressing Tet-shRNA targeting Renilla luciferase (REN) as negative control or Tet-shRNAs targeting CPS1, and stable integrants were obtained by flow cytometry (FACS Aria II SORP). The primers used to generate shCPS1 constructs were as follows: shCPS1-1 forward, 5 ′ -T GC TG TT GA CA GT GA GC GC AA CC AA GG AT GT CA AA GT GTATAGTGA AGCCACA-3′ , shCPS1-2 forward, 5′ -TGCTGTTGACAGTGAGCGCACCAAG GATGTCAAAGTGTACTAGTGAAGCCACA-3′ .
All nucleosides (uridine, thymidine and adenosine), citrulline, ornithine and NaNO 2 were purchased from Sigma-Aldrich. Doxycycline was from Research Products International (RPI), Torin 1 and cisplatin were from Selleckchem and A769662 was from Tocris Bioscience. Metabolomics. NSCLC cell lines were plated at 3-5 × 10 6 cells per 10-cm plate for 16 h before collection. Two hours before collection, cells were incubated with fresh media. At the time of collection, cells were washed with ice-cold saline, lysed with 80% methanol in water and quickly scraped into an Eppendorf tube followed by three freeze-thaw cycles in liquid nitrogen. The insoluble material was pelleted in a cooled centrifuge (4 °C) and the supernatant was transferred to a new tube and evaporated to dryness using a SpeedVac concentrator (Thermo Savant). Metabolites were reconstituted in 100 μ l of 0.03% formic acid in LCMS-grade water, vortex-mixed and centrifuged to remove debris. For human NSCLC metabolomics, frozen tissues were weighed and divided into 3-9 fragments (around 3 mg per fragment) for technical replicates. Fragments were homogenized in 80% methanol in water and centrifuged at 14,000g for 15 min (4 °C). The supernatant was transferred to a new tube and evaporated to dryness as described above for cell lysates. Samples were randomized and blinded before analysing by LC-MS/MS. LC-MS/ MS and data acquisition were performed using an AB QTRAP 5500 liquid chromatography/triple quadrupole mass spectrometer (Applied Biosystems SCIEX) as described previously 24 with an injection volume of 20 μ l. Carbamoyl phosphate was detected in negative mode by monitoring ions 140 and 79 in Q1 and Q3, respectively. Chromatogram review and peak area integration were performed using MultiQuant software version 2.1 (Applied Biosystems SCIEX), and the peak area for each detected metabolite was normalized against the total ion count of that sample to correct for any variations introduced by sample handling through instrument analysis. The normalized areas were used as variables for the multivariate and univariate statistical data analysis. All multivariate analyses and modelling on the normalized data were carried out using Metaboanalyst 3.0 (http://www. metaboanalyst.ca). Univariate statistical differences of the metabolites between two groups were analysed using a two-tailed Student's t-test. NH 4 Cl for 4 h before collection. At the time of collection, the cells were washed with ice-cold saline, lysed with 40% methanol:40% acetonitrile:20% water with 0.1 M formic acid and processed as described above (Metabolomics). Metabolites were reconstituted in 100 μ l of 0.1% formic acid in LCMS-grade water, vortex-mixed and centrifuged to remove debris. Samples were randomized and blinded before analysing by LC-MS/MS. LC-MS/MS and data acquisition were performed as described previously on an AB SCIEX QTRAP 5500 (ref. 24 ) with slight modifications. In brief, the mobile phases used were 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B). The gradient program was as follows: 0-3 min, 0% B; 3-4 min, 0%-100% B; 4-5 min, 100% B; 5-5.1 min, 100%-0% B; 5.1-6 min, 0% B. The column was maintained at 35 °C and the samples were kept in the autosampler at 4 °C. The flow rate was 0.5 ml min −1 and the injection volume was 20 μ l. Sample analysis was performed in positive mode. Declustering potential (DP), collision energy (CE) and collision cell exit potential (CXP) were optimized by direct infusion of reference standards using a syringe pump before sample analysis. Q1, Q3, DP, CE, CXP, retention time and dwell time for each transition of thymidine are in Supplementary Table 10 . The MRM MS/MS detector conditions were set as follows: curtain gas 30 psi; ion spray voltages 1,200 V; temperature 650 °C; ion source gas 1, 50 psi; ion source gas 2, 50 psi; interface heater on; entrance potential 10 V. Dwell time for each transition was set at 3 ms. Samples were analysed in a randomized order, and MRM data was acquired using Analyst 1.6.1 software (Applied Biosystems SCIEX). Metabolic assays. To measure NOS activity, 10,000 cells were cultured in a 96-well plate for 16 h before the assay, and free NO was quantified with a spectrophotometric assay (Sigma-Aldrich). For ammonia secretion, cells were cultured in fresh RPMI for 6 h and ammonia was measured with a spectrophotometric assay (Megazyme). In this assay, glucose deprivation induces ammonia secretion 25 and was used as a positive control for the effect of CPS1 silencing on ammonia secretion in Extended Data Fig. 9b . For arginine deprivation and metabolite rescue experiments (citrulline, ornithine and NaNO 2 ), NSCLC cells were plated in 96-well plates at 3,000-5,000 cells per well. The following day, the culture medium was changed either to complete RPMI or arginine-depleted RPMI with or without 1 mM citrulline, 1 mM ornithine or 3 mM NaNO 2 . Cell viability was assayed three days later using CellTiter-Glo (Promega). Cell growth, cell death and viability. To monitor proliferation in a monolayer culture, 1-3 × 10 5 cells were seeded in a 6-cm dish. Every three days, cells were trypsinized and counted with a haemocytometer. The live cell content was estimated using a CellTiter-Glo assay (Promega). To examine cell death, cells were treated as indicated in the figure legend and stained with propidium iodide or with Annexin-V-FITC and propidium iodide. Cells were then analysed by flow cytometry (FACS Aria II SORP). Soft-agar colony-formation assay. Four days after Dox induction, cells (1,000 per well) were suspended in 0.375% agar (Noble agar, Difco) pre-equilibrated with growth medium, over a 0.75% bottom agar layer in each well of a 6-well plate. Colonies were allowed to form for 20-22 days with intermittent medium supplementation (a few drops twice a week). Images were acquired with G box-Syngene (Syngene) and colonies were detected with GeneTools software (Syngene). BrdU incorporation assay. Cells were labelled with BrdU labelling (10 μ M) for 1 h followed by fixation. Incorporated BrdU was detected by immunostaining and quantified by FACS analysis. DNA fibre assay. Cells were labelled with 100 μ M iododeoxyuridine (IdU) for 10 min, then with 100 μ M chlorodeoxyuridine (CldU) for 20 min. DNA fibres were spread as described previously 26 and stained with primary antibodies (mouse antiBrdU/IdU from BD Bioscience; rat anti-BrdU/CldU from Accurate Chemical) and fluorescence-conjugated secondary antibodies (Alexa Fluor 488-anti-rat and TexasRed-conjugated anti-mouse from Invitrogen). Fibres were imaged using Zeiss Axio Imager M2 and measured using AxioVision software (SE64 version 4.9.1). qRT-PCR. RNA was extracted in TRIzol (Invitrogen) and isolated according to the manufacturer's protocol. cDNA was generated using the iScript synthesis kit (Bio-Rad), and abundance was measured on a Thermo qPCR instrument. Data were normalized to β -actin (ACTB) or GAPDH. Primers used for qRT-PCR were as follows: CPS1 forward, 5′ -ATTCCTTGGTGTGGCTGAAC-3′, reverse, 5′-ATGGAAGAGAGGCTGGGATT-3′; ARG2 forward, 5′-GAGAA GCTGGCTTGATGAAA-3′, reverse, 5′-CAGCTCTGCTAACCACCTCA-3′; ASS1 forward, 5′-CTGATGGAGTACGCAAAGCA-3′, reverse, 5′-CTCGAGAAT GTCAGGGGTGT-3′; ADC forward, 5′-CCTCAGGCCTATGCTCAGTC-3′, reverse, 5′-CTGAGTTGATCACGGAAGCA-3′; AGMAT forward, 5′-CGACCT TGGATCCCTACAGA-3′, reverse, 5′-ACCAGCAATTTCAGGTGTCC-3′; CAD forward, 5′-TCAAGGTGACCCAGCACCTG-3′, reverse, 5′-TCAGGCAAA GGGATGCCCAA-3′; actin forward, 5′-AGAGCTACGAGCTGCCTGAC-3′, reverse, 5′-AGCACTGTGTTGGCGTACAG-3′, GAPDH forward, 5′-ACCCA GAAGACTGTGGATGG-3′, reverse, 5′ -TTCAGCTCAGGGATGACCTT-3′ . RNA interference (RNAi). Transient gene-silencing experiments were performed with endoribonuclease-prepared siRNAs (esiRNA, Sigma-Aldrich) for CPS1 and CAD, and with ON-TARGETplus-SMART pools (Dharmacon) for LKB1, CREB1, FOXA1, TEAD4, ODC, TSC-1 and TSC-2, AMPKα -1 (PRKAA1) and AMPKα -2 (PRKAA2). In brief, siRNA oligos were transfected into cells with RNAiMAX transfection reagent (Invitrogen); esiRNA oligos targeting eGFP or siRNA universal negative controls were used as a negative control (Sigma-Aldrich). For Extended Data Figs 6e, 10d, triple transfections were performed (every other day, repeated three times) and western blots were assayed 144 h after the first transfection. Viability assays were performed after 96 h and cell death analyses and all other western blots were performed after 48 h. BrdU incorporation was measured after 24 h in H460 cells and after 36 h in H2122 cells. For inducible RNAi experiments, shREN and shCPS1-1 and shCPS1-2 were induced using doxycycline concentrations of 1.0-2.0 mg ml
ChIP-qPCR.
ChIP experiments were performed as described 27 with modifications. In brief, around 1-2 × 10 7 cells were crosslinked with 1% formaldehyde for 5 min at room temperature. Chromatin was sonicated to around 500 bp in RIPA buffer (10 mM Tris-HCl, 1 mM EDTA, 0.1% sodium deoxycholate, 0.1% SDS, 1% Triton X-100, 0.25% sarkosyl, pH 8.0) with 0.3 M NaCl. Sonicated chromatin samples were incubated with 5 μ g antibody at 4 °C. After overnight incubation, protein A or G Dynabeads (Invitrogen) were added to the ChIP reactions and incubated for four additional hours at 4 °C to collect the immunoprecipitated chromatin. Subsequently, Dynabeads were washed twice with 1 ml of RIPA buffer, twice with 1 ml of RIPA buffer with 0.3 M NaCl, twice with 1 ml of LiCl buffer (10 mM Tris-HCl, 1 mM EDTA, 0.5% sodium deoxycholate, 0.5% NP-40, 250 mM LiCl, pH 8.0), and twice with 1 ml of TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0). The chromatin was eluted in SDS elution buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.0) followed by reverse crosslinking at 65 °C overnight. ChIP DNA were treated with RNaseA (5 μ g ml
) and protease K (0.2 mg ml −1 ) and purified using QIAquick Spin Columns (Qiagen). The purified ChIP DNA was quantified by real-time PCR using the iQ SYBRGreen Supermix (Bio-Rad). The following antibodies were used: H3K27ac (Abcam, ab4729), H3K4me3 (Millipore, 04-745,), RNAPII (Santa Cruz Biotechnology, sc-899), FOXA1 (Abcam, ab23738), TEAD4 (Abcam, ab58310), CREB1 (Santa Cruz Biotechnology, sc-186) and IgG (Millipore, 12-370). Other ChIP-seq datasets were obtained from previous publications or the ENCODE project. Primers used for CPS1 qPCR were as follows: control forward, 5′-AAACCCACGTCCAGCACAGTGTC-3′ , reverse, 5′-AATAGCGGGTAAGGATGTAGACAGG-3′ ; promoter forward, 5′-TTAACCCACCCGGACAAAGAGG-3′ , reverse, 5′-AATAGCCCTTCTGTTA CTGTCC-3′ ; enhancer 1 forward, 5′-CCTGCCCTATGACTCAACTTAC-3′ , reverse, 5′-GGAAATCGGAAATAGGACCCGTGC-3′; enhancer 2 forward, 5′-CCACATGCTTCTCTGTGATCCTC-3′, reverse, 5′ -ATTCTAAAGAGCA ACCCTAGCTG-3′. Primers used for CAD qPCR were as follows: promoter 1 forward, 5′-TCCTTCCCGCTTCTCCGTACTCG-3′ , reverse, 5′-CACAGAG TGGGATAAGGTCTGC-3′; promoter 2 forward, 5′-AGCCCAGCCCTGCTTC TTTCTTGC-3′, reverse, 5′ -GGGATGCCATAGTTGCCGATCAGAG-3′ . CRISPR-Cas9-mediated recombination. CPS1-deficient H460 clones for isotope tracing were generated using the original CRISPR-Cas9 system 28 and pools for cell viability assays were generated using the lentiCRISPR V2 system 29 . To control for variations among individual clones in the tracing experiments, 4-5 clones were pooled together. Guide-RNA oligos were as follows:
forward, 5′ -CACCG ACAATGGCCAACCCTATTAT-3′ , reverse, 5′ -AAACATA ATAGGGTTGGCCATTGTC-3′ . Western blot analysis. Protein lysates were prepared in either RIPA or CHAPS buffer and quantified using the BCA protein assay (Thermo Scientific). Proteins were separated on 4-20% SDS-PAGE gels, transferred to PVDF membranes, and probed with antibodies against CPS1 (Abcam, ab3682), β -actin (Abcam, ab8227), ASS1 (clone 2B10, Abcam, ab124465), cyclophilin B (clone EPR12703(B), Abcam, ab178397), total AMPK (Cell Signaling, 2603), pAMPK (Cell signaling, 2531), total ACC (Cell Signaling, 3662), pACC (Cell Signaling, 11818), LKB1 (Cell Signaling, 3050), γ H2AX (Cell Signaling, 9718), total CAD (Cell Signaling, 11933), pCAD (Cell Signaling, 12662), NOS3 (BD, 610298), pS6 (Cell Signaling, 2211), p4E-BP1 (Cell Signaling, 2855), CREB1 (Santa Cruz, sc-186X), FOXA1 (ab23738), TEAD4 (ab58310). Xenografts. Animal procedures were performed with the approval of the UT Southwestern IACUC. Tumour size must not exceed 20 mm at the largest diameter and this tumour threshold was never exceeded in any experiment. H460 shREN or shCPS1-1 and shCPS1-2 cells were suspended in RPMI (10 7 per ml), mixed 1:1 with Matrigel (Becton Dickinson), and 10 5 cells for H460 and 10 6 cells for H2122 were implanted subcutaneously into 6-week-old NCRNU mice. After tumour cell injection, mice were randomized and then allocated into cages. Mice were fed regular chow or doxycycline-containing chow (200 mg kg
, Bio-Serv), starting one day after implantation. For cisplatin treatment, tumour-bearing mice were intraperitoneally injected with cisplatin at 2 mg kg −1 or PBS when the xenografted tumours measured around 100 mm 3 . Injections were performed every other day for a total of 5-6 doses. Tumour size was measured every other day with electronic callipers. Tumour volumes were calculated every 3-4 days by calliper measurements of the short (a) and long (b) tumour diameters (volume = a 2 × b / 2) or of tumour height (h), short (a) and long (b) tumour width (volume = h × a × b / 2) depending on tumour shape. Tissue γH2AX staining. Paraffin-embedded tumour sections from mouse xenografts were deparaffinized with xylene followed by ethanol rehydration, fixed in 4% paraformaldehyde and antigens were retrieved with 10 mM sodium citrate pH 6.0. Sections were then subjected to endogenous peroxidase blocking with 0.3% H 2 O 2 . Bovine serum albumin (BSA, 3%) in 0.1% PBST was used as the blocking agent and antibody dilution solution. After 1 h blocking, samples were incubated overnight at 4 °C with the primary antibody (Cell Signaling, 9718) followed by incubation with fluorescence-conjugated secondary antibodies (ThermoFisher Scientific, A-21206). Images were acquired as a series of 0.4-μ m stacks with a DeltaVision system (Applied Precision). Raw images were deconvolved using the iterative algorithm implemented in the softWoRx software (Applied Precision). TUNEL assay. Cell death was detected in xenografts using the In Situ Cell Death Detection kit, Fluorescein (Sigma-Aldrich) according to the manufacturer's protocol. In brief, tissue sections were deparaffinized with xylene and rehydrated with ethanol, then treated with proteinase K (5 μ g ml −1 , New England Biolabs). After washing in PBS, sections were incubated with reaction solution for 1 h at 37 °C in a humidified atmosphere in the dark. Images were acquired with an Olympus IX81 microscope. Human Lung Cancer Tissue Microarray. A tissue microarray with 180 human NSCLC samples (MD Anderson Cancer Center) was probed with antibodies against CPS1 (Sigma-Aldrich, HPA021400) and LKB1 (Cell Signaling, 13752). Immunocytochemistry was performed in a Leica Bond Max (Leica Biosystem) with an antibody dilution at 1:800 for CPS1 and 1:250 for LKB1. Liver tissue was used as a control. Staining intensity was graded as: 0 (no staining); 1+ (weak staining); 2+ (moderate staining); and 3+ (intense staining) by one pathologist, then reviewed by a second pathologist independently. The percentage of stained tumour cells was recorded, and the H-score was assigned using the following formula: 1 × (% cells 1+ ) + 2 × (% cells 2+ ) + 3 × (% cells 3+ ). A final H-score of 0 was assigned as negative; 1-100 as weak; 101-200 as medium; and 201-300+ as strong. Patient survival data. Differences in survival based on either LKB1 mutation or CPS1 mRNA expression was determined in lung adenocarcinoma tumours from The Cancer Genome Atlas (TCGA) (TCGA LUAD provisional). The analysis was restricted to the 230 tumours that had undergone both whole-exome sequencing and mRNA profiling. Methods for data generation, normalization and bioinformatics analyses were previously described in the TCGA LUAD publication 30 . For the present analysis, data from this cohort was downloaded and analysed using cBioPortal (www.cbioportal.org). mRNA data used for this analysis was RNA Seq V2 RSEM with a z-score threshold of 2.0 applied to identify tumours with high levels of CPS1 upregulation. Statistical analysis. No statistical methods were used to predetermine sample size. Metabolomics and flux analysis samples were randomized before LC-MS/MS analysis. For xenograft experiments, mice injected with tumour cells were randomized before being allocated to cages. All other experiments were not randomized, and the investigators were not blinded to allocation during experiments or to outcome assessment. Experiments in Figs 1a, 2b, 3g with shREN and shCPS1-2, Extended Data Figs 1c, 2, 7i, 8c, 9i, 10j, k were performed once, and experiments in Figs 1d, 3g with shCPS1-1, Fig. 4e , g with shCPS1-2 and Extended Data Figs 6b, 7f, 9e, j, 10b were performed twice. All other experiments were performed three times or more. Variation for xenograft tumour volume is indicated using the standard error of the mean, and variation in all other experiments is indicated using the standard deviation. To assess the significance of differences between two conditions, a two-tailed Welch's unequal variances t-test was used. Where the data points showed a skewed distribution (for example, Extended Data Fig. 1c) , a Wilcoxon signed-rank test was performed. For comparisons among three or more groups, a one-way ANOVA followed by Tukey's multiple comparisons test was performed. To examine significance in xenograft tumour growth between two or among three or more groups, a two-way ANOVA followed by Tukey's multiple comparisons test was performed. Before applying an ANOVA, we first tested whether there was homogeneity of variation among the groups (as required for ANOVA) using the Brown-Forsythe test. In all xenograft assays, we injected 6-7-week-old NCRNU mice (both male and female), 10 mice per treatment (except Extended Data Fig. 10j , k: n = 4 per group), as we expected based on previous pilot experiments to observe differences in tumour size after two weeks. When mice died before the end of experiments, data from those mice were excluded (Fig. 3g for shCPS1-2 − Dox) . Data availability. All primary data are included in the Source Data associated with each figure accompanying this Letter. Any additional information required to interpret, replicate or build upon the Methods or findings reported in the manuscript are available upon request from the corresponding author. Figure 2 | Metabolomic profiling of KL and K cancer cells and human NSCLC. Left, relative abundance of metabolites extracted from five KL (H157, A549, H460, H2122, H1355) and five K (Calu-1, Calu-6, H1373, H358, H441) cell lines. Peak areas of each metabolite were normalized by total ion count and the heat map displays the average value for each metabolite; n = 4 independent cultures for each cell line. Right, relative abundance of metabolites extracted from four KL human tumours (tumours 5-, 8-, 9-and 11-KL) and seven K human tumours (tumours 1-, 2-, 3-, 4-, 6-, 7-and 10-K). Peak areas of each metabolite were normalized by total ion count followed by mean normalization and the heat map displays the average value for each metabolite; n = 3 independent fragments for each tumour except tumour 2-K (n = 6), tumour 8-KL (n = 6) and tumour 1-K (n = 9). KL cell lines or tumours are indicated in red, K cell lines or tumours are indicated in blue. The colours in the heat map reflect a log 2 scale.
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